Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
February 14, 2017 8:47 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Outperform rating and $42 price target on Teva Pharmaceuticals Industries (NYSE: TEVA), suggesting strategic questions remain, despite the company reporting 2016 fourth quarter results above consensus.
Stanicky comments, "TEVA reported 4Q above Street expectations and reaffirmed 2017... More
Teva Pharma (TEVA) Weighing Options for Branded Generics Unit to Cut Debt - Bloomberg
February 13, 2017 11:35 AM EST(Updated - February 13, 2017 11:41 AM EST)
Teva Pharma (NYSE: TEVA) is weighing options for its branded generics unit in an effort to reduce debt, Bloomberg reported citing people familiar with the mater.
The unit could be valued at several billion dollars, and... More
Teva Pharma (TEVA) volatility comes in after solid Q4 and outlook
February 13, 2017 11:26 AM ESTTeva Pharma (NYSE: TEVA) February call option implied volatility is at 38 compared to a level of 56 from last week, March is at 31; compared to its 52-week range of 19 to 50 after solid Q4 and outlook.
... MoreTeva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms
February 13, 2017 6:43 AM EST(Updated - February 13, 2017 6:44 AM EST)
Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.38, $0.02 better than the analyst estimate of $1.36. Revenue for the quarter came in at $6.5 billion versus the consensus estimate of $6.26 billion.
Teva reaffirms its 2017 full year non-GAAP guidance; including revenues of $23.8 - 24.5 billion, and non-GAAP EPS of $4.90 - 5.30
"2016 was a transitional year for Teva - one that... More
